Drug Approval | May 15, 2026
Lupin receives USFDA nod for Famotidine injection
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets are indicated for the treatment of human immunodeficiency virus infection in adults and pediatric patients weighing at least 25 kg
Oxcarbazepine ER Tablets (RLD Oxtellar XR) had estimated annual sales of US$ 206 million in the US (IQVIA MAT April 2025)
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
The fixed-dose combination of Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg tablets for oral suspension is a once-daily single-pill regimen
This product will be manufactured at Lupin’s Nagpur facility in India
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
The product will be manufactured at Lupin’s Nagpur facility in India
This product will be manufactured at Lupin's Nagpur facility in India
Subscribe To Our Newsletter & Stay Updated
